Hematogenous or lymphatic spread of Mycobacterium tuberculosis causing osteolytic spinal lesions with drug resistance to isoniazid, rifampicin, and fluoroquinolones
Target Population
Patients with spinal TB, particularly in high TB burden regions or with risk factors for drug resistance
Care Setting
Specialized hospital settings with access to advanced imaging, microbiological diagnostics, and expert infectious disease consultation
Key Highlights
Spinal TB is a rare extrapulmonary manifestation with slow progression and often delayed diagnosis due to nonspecific symptoms.
Pre-XDR TB involves resistance to isoniazid, rifampicin, and fluoroquinolones, complicating treatment selection and duration.
Microbiological confirmation and antimicrobial susceptibility testing (AST) are essential but challenging due to paucibacillary nature and specimen acquisition difficulties.
Guideline-Based Recommendations
Diagnosis
Obtain detailed clinical history including TB exposure and risk factors.
Use imaging modalities (X-ray, CT, MRI) to assess spinal involvement and complications.
Perform biopsy and microbiological testing including smear microscopy, nucleic acid amplification tests (NAATs) like GeneXpert MTB/RIF and MTB/XDR, and culture for definitive diagnosis and AST.
Management
Initiate individualized treatment based on rapid molecular AST and expert consultation.
Use combination therapy including amikacin, bedaquiline, linezolid, cycloserine, ethionamide, and pyrazinamide as guided by susceptibility and tolerability.
Plan prolonged treatment duration (15–18 months) guided by clinical and radiological response.
Adjust therapy based on adverse effects and emerging clinical findings, e.g., replacing linezolid and cycloserine with delamanid if toxicity occurs.
Monitoring & Follow-up
Perform weekly laboratory tests including amikacin trough levels, complete blood counts, liver and kidney function.
Conduct monthly assessments of thyroid function, audiometry, and electrocardiograms.
Monitor for clinical side effects such as peripheral neuropathy and photophobia with appropriate investigations.
Risks
Delayed diagnosis due to indolent course and nonspecific symptoms.
Treatment complications from drug toxicity and adverse effects.
Potential for neurological deficits from spinal cord compression if untreated.
Challenges in obtaining adequate specimens for microbiological confirmation.
Patient & Prescribing Data
Young adult with pre-XDR spinal TB and no prior health issues
Combination therapy tailored by rapid molecular susceptibility testing and expert input led to full neurological recovery; treatment required prolonged duration with adjustments for drug toxicity.
Clinical Best Practices
Early consideration of spinal TB in patients with persistent back pain and constitutional symptoms, especially with epidemiological risk factors.
Use of advanced imaging and surgical biopsy to obtain diagnostic material for microbiological confirmation.
Rapid molecular testing to guide timely initiation of appropriate multidrug regimens.
Close multidisciplinary monitoring for drug toxicity and treatment response.
Expert consultation for individualized treatment planning in drug-resistant spinal TB.
